(Reuters) – Swiss biotech Bioversys AG shares started trading at 36.5 Swiss francs ($40.29) on the SIX Swiss Exchange on Friday, slightly up from the final price for its initial public offering (IPO) of 36 Swiss francs per share.
BioVersys, which researches and develops novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, will use most of its proceeds from the IPO towards the development of its BV100 treatment for infections linked to ventilator-associated pneumonia and bloodstream infections.
($1 = 0.9060 Swiss francs)
(Reporting by Linda Pasquini)
Comments